Skip to main content
. 2020 May 18;11(15):4534–4541. doi: 10.7150/jca.39410

Table 4.

Adverse events occurred after DEB-TACE treatment (126 DEB-TACE records).

Parameters n (%) Grade
Vomiting/Nausea 97/126 (77.0) 1-2
Abdominal pain 77/126 (61.1) 1-2
Aminotransferase elevation 68/126 (54.0) 1-2
Low-grade fever 58/126 (46.0) 1
Decreased strength of the lower limbs for cerebral infarction 2/126 (1.6) 2

Data were presented as count (percentage). The description was based on 126 DEB-TACE records. DEB-TACE, drug-eluting bead transarterial chemoembolization.